Pereira Arturo
Service of Hemotherapy and Hemostasis, Hospital Clínic, Villarroel 170, Barcelona, Spain.
Haematologica. 2007 Jun;92(6):846-9. doi: 10.3324/haematol.11072.
A probabilistic model was used to compare cryoprecipitate to viral inactivated, commercial fibrinogen concentrate to evaluate with regard to the recipient's risk of exposure to an emergent AIDS-like epidemic. In patients who occasionally need a therapeutic dose of fibrinogen, commercial fibrinogen would be marginally safer than cryoprecipitate if the new pathogen were sensitive to inactivation. But there is a potential high risk of exposure if the emerging agent withstands inactivation. In most of the analyzed scenarios, cryoprecipitate is safer than commercial fibrinogen as long as the odds that the new agent is sensitive to inactivation are lower than 1.000 to 1.
使用概率模型比较冷沉淀与病毒灭活的商业纤维蛋白原浓缩物，以评估接受者暴露于类似艾滋病的新出现流行病的风险。对于偶尔需要治疗剂量纤维蛋白原的患者，如果新病原体对灭活敏感，商业纤维蛋白原比冷沉淀略微安全。但如果新出现的病原体能够耐受灭活，则存在潜在的高暴露风险。在大多数分析的情况下，只要新病原体对灭活敏感的几率低于1000比1，冷沉淀就比商业纤维蛋白原更安全。
